Hematologic Diseases
Expanding access to hematopoeitic stem cell transplants for patients in need
Program
Phase 1
Phase 2
Phase 3
Commercial
-
BMT Comparative Study
Phase 2
A multi-center Phase 2 trial of partially HLA-mismatched (>4/8) , unrelated bone marrow for transplantation to treat hematologic malignancies (MDS, AML, CLL, ALL, etc.). Study will compare the effectiveness of mismatched Ossium HPC, Marrow to live donor haploidentical transplants.
Related Products
HPC, Marrow
Partners
Be The Match / NMDP
-
Micro Bone Marrow Transplants
Phase 1
Phase 1 safety and feasibility clinical trial for blood cancers where patients will receive a reduced (‘micro’) conditioning regimen and a mismatched bone marrow transplant using Ossium HPC, Marrrow
Related Products
HPC, Marrow
Partners
Columbia University
Organ Transplant Rejection
Allowing organ transplant recipients patients to lead healthy lives without immunosuppression
Program
Pre-Clinical
Phase 1
Phase 2
Phase 3
Commercial
-
Upper Extremity (vascular composite allografts)
Phase 2
Phase 2 study with the objective of inducing a tolerogenic state after vascularized composite allotransplantation (VCA) of upper extremities via infusion of HPC-Marrow processed from the VCA donor.
Related Products
HPC, Marrow
Partners
Johns Hopkins University
-
Multivisceral Transplantation
Phase 1
Phase 1 safety and feasibility study with the objective of inducing tolerance in intestinal transplant patients by establishing mixed chimerism via infusion of Ossium’s CD34+ Selected Cells processed from the organ donor's bone marrow.
Related Products
CD34+ Selected Cells
Partners
Columbia University
Diseases of Inflammation
Mesenchymal Stem Cells (MSCs) modulate immune function and inflammation, providing a promising option for the treatment of diseases characterized by the presense of an inflammatory component
Program
Pre-Clinical
Phase 1
Phase 2
Phase 3
Commercial
-
Crohn's Perianal Fistula
Phase 2
Phase 2 study determining the effectiveness of a perilesional injection of 100 million BM-MSCs for the treatment of refractory perianal fistulizing Crohn’s
Related Products
Ossium MSCs
Partners
Cleveland Clinic
-
Graft-versus-Host Disease (GVHD)
Phase 1
Open label, non-randomized Phase I evaluating the use of interfeon gamma-primed MSCs to prevent graft-versus-host disease in adult and pediatric patients undergoing HSCT for acute leukemia and myelodysplastic syndromes
Related Products
Ossium MSCs
Partners
Emory University
-
Asthma
Phase 1
Phase 1 safety and efficacy study evaluating the use of interferon gamma-primed MSCs in children with moderate-to-severe persistent asthma
Related Products
Ossium MSCs
Partners
Childrens Hospital of Atlanta